Report of the international conference on manufacturing and testing of pluripotent stem cells.

Biologicals : Journal of the International Association of Biological Standardization
Stewart AbbotKathryn Zoon

Abstract

Sessions included an overview of past cell therapy (CT) conferences sponsored by the International Alliance for Biological Standardization (IABS). The sessions highlighted challenges in the field of human pluripotent stem cells (hPSCs) and also addressed specific points on manufacturing, bioanalytics and comparability, tumorigenicity testing, storage, and shipping. Panel discussions complemented the presentations. The conference concluded that a range of new standardization groups is emerging that could help the field, but ways must be found to ensure that these efforts are coordinated. In addition, there are opportunities for regulatory convergence starting with a gap analysis of existing guidelines to determine what might be missing and what issues might be creating divergence. More specific global regulatory guidance, preferably from WHO, would be welcome. IABS and the California Institute for Regenerative Medicine (CIRM) will explore with stakeholders the development of a practical and innovative road map to support early CT product (CTP) developers.

Citations

Jan 18, 2019·Regenerative Medicine·Shane A ShapiroZubin Master
Sep 22, 2020·Current Protocols in Stem Cell Biology·Aya ShibamiyaBärbel Maria Ulmer
Oct 25, 2020·Biologicals : Journal of the International Association of Biological Standardization·Jiaqi Lu, Wei Wei
Aug 19, 2021·The FEBS Journal·Hiraku Tsujimoto, Kenji Osafune

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.